INRLF (Valneva SE) 9-Day RSI: 54.23 (As of Jul. 07, 2026)


INRLF Valneva SE INRLF
55 GF Score
Price $2.62
GF Value $2.76
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Valneva SE 9-Day RSI?

Valneva SE INRLF 55 9-Day RSI is 54.23 as of Jul. 07, 2026. GuruFocus rates INRLF with a GF Score™ of 55/100 and a GF Value™ of $2.76 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,417 Biotechnology companies, Valneva SE ranks better than 51.31% on this metric.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-07), Valneva SE's 9-Day RSI is 54.23.

The industry rank for Valneva SE's 9-Day RSI or its related term are showing as below:

INRLF's 9-Day RSI is ranked better than
51.31% of 1417 companies
in the Biotechnology industry
Industry Median: 53.73 vs INRLF: 54.23

Valneva SE  (OTCPK:INRLF) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Valneva SE 9-Day RSI Related Terms


INRLF vs VRTX, REGN, ALNY: 9-Day RSI Comparison

For the Biotechnology subindustry, Valneva SE's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Valneva SE 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valneva SE's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Valneva SE's 9-Day RSI falls into.


INRLF
55GF Score
Valneva SE INRLF
9-Day RSI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Valneva SE  (OTCPK:INRLF) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 9-Day RSI →
What does a 9-Day RSI of 54.23 mean?
Valneva SE (INRLF) has a 9-Day RSI of 54.23 as of Jul. 07, 2026. According to the industry distribution chart, Valneva SE ranks #690 out of 1417 companies in the Biotechnology industry, placing it in the top 48.7%.
Is Valneva SE's 9-Day RSI too high?
Valneva SE's current 9-Day RSI is 54.23. The Biotechnology industry median 9-Day RSI is 53.73. Valneva SE's value of 54.23 is 0.9% above this industry median. Based on the distribution chart, Valneva SE ranks #690 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Valneva SE has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Valneva SE's 9-Day RSI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valneva SE ranks #690 out of 1417 companies for 9-Day RSI. This puts Valneva SE in the upper half of its industry. The industry median 9-Day RSI is 53.73. Valneva SE's value of 54.23 is 0.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 53.73, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valneva SE's current 9-Day RSI of 54.23 is 0.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 53.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valneva SE's current 9-Day RSI is 54.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valneva SE stock overvalued right now?
Based on GuruFocus' analysis, Valneva SE (INRLF) is currently considered Fairly Valued. The stock's GF Value™ is $2.76, compared to a current price of $2.62 — trading 5.1% below its estimated fair value. The current 9-Day RSI is 54.23 and 0.9% above the Biotechnology industry median of 53.73. Valneva SE's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Valneva SE (INRLF), the current 9-Day RSI is 54.23 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Valneva SE (INRLF) Overvalued in 2026?

Based on GuruFocus' analysis, Valneva SE stock appears to be undervalued. The current stock price of $2.62 is trading 5.1% below its estimated GF Value™ of $2.76. GuruFocus considers Valneva SE to be Fairly Valued.

Key valuation signals for INRLF:

  • 9-Day RSI: 54.23
  • GF Value™: $2.76 vs. price of $2.62 (5.1% below fair value)
  • GF Score™: 55/100 with 6 warning signs
  • Industry Position: 0.9% above the Biotechnology median (#690 of 1417)

No single metric tells the full story. See the INRLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Valneva SE Business Description

Address 12 ter Quai Perrache, Bureaux Convergence, Bat. A, Ilot Saint-Joseph, Lyon, FRA, 69002
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
55GF Score

Get the complete analysis for INRLF

9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.62
Price
$2.76
GF Value